3-((4-((thiophen-2-ylmethyl)amino)quinazolin-2-yl)amino)phenol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-((4-((thiophen-2-ylmethyl)amino)quinazolin-2-yl)amino)phenol
• 英文别名: 3-[[4-(Thiophen-2-ylmethylamino)quinazolin-2-yl]amino]phenol；3-[[4-(thiophen-2-ylmethylamino)quinazolin-2-yl]amino]phenol
• 化学式: C₁₉H₁₆N₄OS
• 分子量: 348.428
• InChiKey: CDZMGDGFWNZTAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  98.3
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• [EN] QUINAZOLINE COMPOUNDS AS MODULATORS OF RAS SIGNALING<br/>[FR] COMPOSÉS DE QUINAZOLINE UTILISÉS EN TANT QUE MODULATEURS DE SIGNALISATION RAS
  申请人：UNIV VANDERBILT

  公开号：WO2018212774A1

  公开（公告）日：2018-11-22

  The present invention relates to quinazoline compounds and compositions that modulate Ras signaling. Compounds and compositions of the present invention are useful in the treatment of cancers and other disease states associated with Ras dysfunction (e.g., Ras-associated autoimmune leukoproliferative disorder, or certain types of mitochondrial dysfunction) in a subject, for example a mammal or a human.

  本发明涉及喹唑啉化合物和调节Ras信号传导的组合物。本发明的化合物和组合物在治疗癌症和其他与Ras功能失调相关的疾病状态（例如与Ras相关的自身免疫性白细胞增生性疾病，或某些类型的线粒体功能障碍）中具有用途，例如在主体中，例如哺乳动物或人类。
• Quinazoline compounds as modulators of Ras signaling
  申请人：VANDERBILT UNIVERSITY

  公开号：US11318137B2

  公开（公告）日：2022-05-03

  The present invention relates to quinazoline compounds and compositions that modulate Ras signaling. Compounds and compositions of the present invention are useful in the treatment of cancers and other disease states associated with Ras dysfunction (e.g., Ras-associated autoimmune leukoproliferative disorder, or certain types of mitochondrial dysfunction) in a subject, for example a mammal or a human.

  本发明涉及调节 Ras 信号转导的喹唑啉化合物和组合物。本发明的化合物和组合物可用于治疗受试者（例如哺乳动物或人类）的癌症和其他与 Ras 功能障碍相关的疾病状态（例如 Ras 相关自身免疫性白细胞增殖障碍或某些类型的线粒体功能障碍）。
• QUINAZOLINE COMPOUNDS AS MODULATORS OF RAS SIGNALING
  申请人：VANDERBILT UNIVERSITY

  公开号：US20200253974A1

  公开（公告）日：2020-08-13

  The present invention relates to quinazoline compounds and compositions that modulate Ras signaling. Compounds and compositions of the present invention are useful in the treatment of cancers and other disease states associated with Ras dysfunction (e.g., Ras-associated autoimmune leukoproliferative disorder, or certain types of mitochondrial dysfunction) in a subject, for example a mammal or a human.